Enterprise Value
573M
Cash
325.9M
Avg Qtr Burn
-69.73M
Short % of Float
21.06%
Insider Ownership
10.43%
Institutional Own.
92.79%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SC291 (CD19) Details B-cell malignancies | Phase 1 Data readout |